[
  {
    "ts": null,
    "headline": "FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis",
    "summary": "RAHWAY, N.J., February 25, 2026--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be a",
    "url": "https://finnhub.io/api/news?id=5099c3319a2a055141b7af404ef36cdce106eae0984c445c025fe2dd6caf11a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772055000,
      "headline": "FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis",
      "id": 139225111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 25, 2026--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Food and Drug Administration (FDA) approval of NUMELVI™ (atinvicitinib tablets) – the first and only second-generation Janus kinase (JAK) inhibitor indicated for the control of pruritus associated with allergic dermatitis in dogs six months of age and older. The product is expected to be a",
      "url": "https://finnhub.io/api/news?id=5099c3319a2a055141b7af404ef36cdce106eae0984c445c025fe2dd6caf11a3"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
    "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
    "url": "https://finnhub.io/api/news?id=8f89cc05824cb2ac825f2a3f542aad6335186195d3777aab1741548f68c0dc95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772041080,
      "headline": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
      "id": 139223955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
      "url": "https://finnhub.io/api/news?id=8f89cc05824cb2ac825f2a3f542aad6335186195d3777aab1741548f68c0dc95"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026",
    "summary": "RAHWAY, N.J., February 25, 2026--Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026",
    "url": "https://finnhub.io/api/news?id=5176325f7aa56838720593d5839d62e769588caa20dbacda2d34dd94255bed80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772041020,
      "headline": "Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026",
      "id": 139215495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 25, 2026--Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026",
      "url": "https://finnhub.io/api/news?id=5176325f7aa56838720593d5839d62e769588caa20dbacda2d34dd94255bed80"
    }
  },
  {
    "ts": null,
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772031440,
      "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
      "id": 139210537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
      "url": "https://finnhub.io/api/news?id=fd179c9bbe20abdd9972864ad70fb56fd3bd3c1f562aeee5619e9286e4076039"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=fca9d70d1c8fb425f963ceb78812aca9f2403c3c7c78442d45dd4db5d25482e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772028005,
      "headline": "Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock",
      "id": 139210597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=fca9d70d1c8fb425f963ceb78812aca9f2403c3c7c78442d45dd4db5d25482e5"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
    "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
    "url": "https://finnhub.io/api/news?id=ba45cee31689e9da54a64d074b4fc30860d13dcf0660dec8cbfde6c06856b970",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772027340,
      "headline": "Can J&J Sustain Its Double-Digit Oncology Growth Streak?",
      "id": 139210551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "JNJ's oncology sales surged in 2025 as Darzalex and new drugs powered growth. With a $50B target by 2030, can its cancer momentum last?",
      "url": "https://finnhub.io/api/news?id=ba45cee31689e9da54a64d074b4fc30860d13dcf0660dec8cbfde6c06856b970"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Coverage of Merck (MRK) with Outperform Recommendation",
    "summary": "RBC Capital Initiates Coverage of Merck (MRK) with Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=79f562d0f51a96ea326d80645378c7128b9b50fca2bd4a506c96088032101cc5",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772024609,
      "headline": "RBC Capital Initiates Coverage of Merck (MRK) with Outperform Recommendation",
      "id": 139208869,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=79f562d0f51a96ea326d80645378c7128b9b50fca2bd4a506c96088032101cc5"
    }
  },
  {
    "ts": null,
    "headline": "GSK to acquire 35Pharma in $950M deal for cardiovascular drug",
    "summary": "The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.",
    "url": "https://finnhub.io/api/news?id=a81cd9b6f16da5a80e3273c7a9587c7837d9f12377974288787950e6a9ef9b29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772012584,
      "headline": "GSK to acquire 35Pharma in $950M deal for cardiovascular drug",
      "id": 139215496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.",
      "url": "https://finnhub.io/api/news?id=a81cd9b6f16da5a80e3273c7a9587c7837d9f12377974288787950e6a9ef9b29"
    }
  },
  {
    "ts": null,
    "headline": "GSK secures potential ‘multi-blockbuster’ drug in $950mn deal",
    "summary": "GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as part of a drive...",
    "url": "https://finnhub.io/api/news?id=0b8517d8f008c8b54bb0937279aa1cff86423c0445506fd85ea68c3ad4804169",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772011612,
      "headline": "GSK secures potential ‘multi-blockbuster’ drug in $950mn deal",
      "id": 139207542,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as part of a drive...",
      "url": "https://finnhub.io/api/news?id=0b8517d8f008c8b54bb0937279aa1cff86423c0445506fd85ea68c3ad4804169"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map",
    "summary": "Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic partnerships, and global presence enhance its competitive edge in healthcare and digital transformation initiatives.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Merck & Co., Inc. 2025\" company profile has been added to ResearchAndMarkets.com's offering. The report pro",
    "url": "https://finnhub.io/api/news?id=82b120cc72c1d3fdc59d35d4b7e79eced7f838cb297e329e36a58192eaeb91fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772010600,
      "headline": "Merck & Co Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Incubators, ICT, Technology Initiatives, Partnerships, Investments, Acquisitions, Network Map",
      "id": 139205949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's market opportunities lie in its broad biopharmaceutical offerings, targeting oncology, vaccines, and more, alongside extensive veterinary solutions. Its tech-driven innovations, strategic partnerships, and global presence enhance its competitive edge in healthcare and digital transformation initiatives.Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The \"Enterprise Tech Ecosystem Series: Merck & Co., Inc. 2025\" company profile has been added to ResearchAndMarkets.com's offering. The report pro",
      "url": "https://finnhub.io/api/news?id=82b120cc72c1d3fdc59d35d4b7e79eced7f838cb297e329e36a58192eaeb91fa"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Coverage On Merck & Co with Outperform Rating, Announces Price Target of $142",
    "summary": "RBC Capital   initiates coverage on Merck &amp; Co (NYSE:MRK) with a Outperform rating and announces Price Target of $142.",
    "url": "https://finnhub.io/api/news?id=ad6e2f1bc5b73aa8bbb4d3dcb32e3161b52ef026b37d50002fb94a9e29e5fca3",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772008533,
      "headline": "RBC Capital Initiates Coverage On Merck & Co with Outperform Rating, Announces Price Target of $142",
      "id": 139207828,
      "image": "",
      "related": "MRK",
      "source": "Benzinga",
      "summary": "RBC Capital   initiates coverage on Merck &amp; Co (NYSE:MRK) with a Outperform rating and announces Price Target of $142.",
      "url": "https://finnhub.io/api/news?id=ad6e2f1bc5b73aa8bbb4d3dcb32e3161b52ef026b37d50002fb94a9e29e5fca3"
    }
  },
  {
    "ts": null,
    "headline": "Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?",
    "summary": "If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is built to help you frame that question clearly. At a last close of US$123.93, Merck's stock has returned 1.9% over 7 days, 14.6% over 30 days, 16.4% year to date, 40.6% over 1 year, 27.8% over 3 years and 109.1% over 5 years. Recent attention on Merck has focused on its broader role in large cap pharmaceuticals, with investors regularly reassessing how its drug portfolio...",
    "url": "https://finnhub.io/api/news?id=c4b2544da650bc964dbb2f24d6bde5ecc21947660fe1f0e8e621939be609d8f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772007234,
      "headline": "Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?",
      "id": 139205950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "If you are wondering whether Merck's share price still offers value after a strong run, you are not alone. This article is built to help you frame that question clearly. At a last close of US$123.93, Merck's stock has returned 1.9% over 7 days, 14.6% over 30 days, 16.4% year to date, 40.6% over 1 year, 27.8% over 3 years and 109.1% over 5 years. Recent attention on Merck has focused on its broader role in large cap pharmaceuticals, with investors regularly reassessing how its drug portfolio...",
      "url": "https://finnhub.io/api/news?id=c4b2544da650bc964dbb2f24d6bde5ecc21947660fe1f0e8e621939be609d8f4"
    }
  }
]